The State of Texas, through the Texas Division of Emergency Management (TDEM), is expanding resources in the Seguin area for a Regional Infusion Center to help treat COVID-19 patients.

The expansion of the infusion center is possible through partnerships between TDEM, Guadalupe Regional Medical Center, the Southwest Texas Regional Advisory Council, the City of Seguin and Guadalupe County.

At Governor Abbott’s request, TDEM, contracting with a private vendor, is providing necessary equipment and staffing to add to the Regional Infusion Center at Guadalupe Regional Medical Center  located in Seguin, Texas. GRMC began administering the monoclonal antibodies on a small scale in December 2020 and transitioned to an infusion center due to increased demand, and is now serving Guadalupe County, Comal County, Wilson County, Caldwell County and others in the region.

The state-supported infusion center will grow operations on Tuesday, September 21. The additional resources for the infusion center will allow for an increased capacity from the current 25-30 daily infusions of a monoclonal antibody treatment to 50 patients per day.

Patients must be confirmed COVID-19 positive and have a referral from a primary care provider. The infusions are meant for COVID-19 patients who are not yet hospitalized or on oxygen supplements.

The infusion center, equipped with monoclonal antibodies, treats COVID-19 patients with therapeutic drugs that may prevent their condition from worsening and requiring hospital care. These centers also help increase bed capacity in hospitals so that resources are available for the most ill patients. The State deployed similar measures back in November 2020 to communities across Texas.

Patients who are eligible for the monoclonal antibody medication:

• Patient must NOT be hospitalized or require oxygen therapy.
• Patient must NOT require an increase in oxygen rate, if using for underlying condition, due to COVID-19.
• Patient MUST be within 10 days of symptom onset.